The need to improve diversity among clinical trial participants has been recognized for some time now, but the issue gained prominence during the COVID-19 pandemic when discussions around inequitable access to research and treatments became more pronounced.
While all eyes are on the US where new legislation has mandated sponsors of Phase III and pivotal trials to develop diversity action plans detailing the rationale and targets for enrolling participants based on age, ethnicity, sex and race, other countries are also taking steps to address the issue
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?